Stock IdeasStrong Buy Stocks

Strong Buy Stocks from Top Wall Street Analysts

Latest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen

JP Morgan's Anupam Rama raised their price target on Oric Pharmaceuticals (NASDAQ: ORIC) by 17.6% from $17 to $20 on 2025/11/18. The analyst maintained their Strong Buy rating on the stock.

Oric Pharmaceuticals reported its Q3 2025 earnings earlier this month.

In a sector overview note, Rama said they adjusted their estimates on smid-cap Biotech names.

Earnings Report

For Q3 2025, Oric Pharmaceuticals reported:

• EPS of $(0.33), which beat the $(0.41) consensus estimate and Q3 2024's $(0.49).
• Revenue (Other Income) of 4.084M, up from Q3 2024's $3.752M.

Management did not provide financial guidance in its press release.

President & CEO Jacob M. Chacko, M.D., commented: “In the first nine months of 2025, we continued to advance toward the potential initiation of Phase 3 trials for ORIC-944 in prostate cancer and enozertinib in lung cancer.

"The ORIC-944 Phase 1b data announced today further support its potential best-in-class efficacy and safety profile, and we look forward to sharing clinical data for enozertinib later this year that will highlight its best-in-class potential.

“Backed by compelling clinical data and a strong cash position, we remain focused on rapidly advancing these programs to registrational studies and, ultimately, commercialization.”